摘要
ITP二线治疗药物利妥昔单抗(RTX)最适应用剂量尚存争议,近年发现小剂量RTX单药及联合用药治疗免疫性血小板减少症(ITP)各有优势。本文就小剂量利妥昔单抗在免疫性血小板减少症治疗中的应用效果研究进展进行综述。
The optimal application dose of Rituximab(RTX),a second-line treatment drug for Immune thrombocytopenia(ITP),is still controversial.In recent years,it has been found that small dose of RTX alone and in combination have advantages in the treatment of ITP.This study reviewed the progress of low dose rituximab in the treatment of immune thrombocytopenia.
作者
黄霖
冯锦山
HUANG Lin;FENG Jinshan(Institute of Hematology,Guangdong Medical University,Zhanjiang,Guangdong 510180,China)
出处
《医药前沿》
2023年第3期40-42,46,共4页
Journal of Frontiers of Medicine
